Novartis to acquire Myricx Bio in up to $1.5bn deal
The acquisition is expected to close in the second half of 2026, pending customary closing conditions and regulatory approvals.
Drug Development
Besins Healthcare boosts drug delivery portfolio with UniD deal
SK bioscience to lead Gates Foundation-funded ROTOR project
European Commission approves Novartis’ Itvisma to treat SMA
Insilico Medicine, Takeda partner on AI-driven drug discovery
Inocras, AimedBio team up for cancer treatments
US FDA rejects approval of Unicycive’s kidney disease therapy
Beyond the GLP-1RA weight loss ceiling
